Whitehawk Therapeutics presents IGCS 2026 ovarian cancer analysis
Whitehawk Therapeutics said it presented real-world analyses supporting MUC16 as a durable ADC target in ovarian cancer at IGCS 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.